VALUTAZIONE DELL'OTOTOSSICITA DELLA DESFERRIOXAMINA IN PAZIENTI TALASSEMICI. RISULTATI DI UN FOLLOW-UP DI 5 ANNI

Translated title of the contribution: Evaluation of desferrioxamine ototoxicity in thalassaemic patients. Follow-up over a 5-year period and results

M. Sacco, D. Meleleo, N. Tricarico, A. Greco Miani, E. Serra, L. Parlatore

Research output: Contribution to journalArticlepeer-review

Abstract

Desferrioxamine (DFO), an iron-chelating drug, up to today has been essential for the care of thalassaemic patients. Unfortunately it presents some toxic effects. One of these is sensorineural hypoacusia, already reported some years ago. In 1987 we documented in our patients a prevalence of 19.4% (7 cases of 36) of sensorineural hypoacusia that proved to be significantly associated with the highest pro kg/die doses of DFO. We made a follow-up audiometry over a 5-year period after a general adjustment of the DFO dosage related to serum Ferritin levels. Four patients with mild hypoacusia (30-50 dB) showed normal audiometry after one year. The hypoacusia of the two severe cases (50-80 dB) proved stable until 5-years later in one case and increased in the other. Only a new case arose denovo. In pathologic patients 'Therapeutic index' (DFO/serum Ferritin) was significantly higher than in normoacusic ones and the 'treshold' value between the two popnlations was of 0.027. We think that the Therapeutic index may be a useful guideline to calculate safe doses of DFO about ototoxicity.

Translated title of the contributionEvaluation of desferrioxamine ototoxicity in thalassaemic patients. Follow-up over a 5-year period and results
Original languageItalian
Pages (from-to)225-230
Number of pages6
JournalMinerva Pediatrica
Volume46
Issue number5
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Evaluation of desferrioxamine ototoxicity in thalassaemic patients. Follow-up over a 5-year period and results'. Together they form a unique fingerprint.

Cite this